Week in Review: Shenzhen's BGI Plans $250 Million China IPO to Support Genomics Operations
June 24, 2017 at 15:20 PM EDT
Known as a world leader in basic science sequencing, BGI now generates 55% of its income from clinical genomic tests, especially its NIFTY prenatal test for hereditary illnesses such as Down's Syndrome.
